ライフサイエンスコーパス: NAFLD

1 NAFLD affected 24.2% of lean patients.

2 NAFLD can range in severity from steatosis to fibrotic s

3 NAFLD develops at the interface between environmental fa

4 NAFLD has a two-fold higher prevalence in HFpEF compared

5 NAFLD is associated with obesity; however, it can occur

6 NAFLD is associated with significant morbidity and morta

7 NAFLD patients had a higher frequency of advanced heart

8 NAFLD patients with evidence of nonalcoholic steatohepat

9 NAFLD was assessed using ultrasonography in the absence

10 NAFLD was diagnosed by transient elastography (TE) and d

11 NAFLD was present in 27% of the full cohort and 50% of t

12 NAFLD-associated liver complications are projected to be

13 3-10.7) or high (HR, 12.6; 95% CI, 4.3-36.3) NAFLD liver fat score, and a high NAFLD fibrosis score (

14 The study consisted of 2,974 NAFLD cases (518 with cirrhosis, 2,456 without cirrhosis

15 54% of NAFLD patients had a NAFLD fibrosis score consistent with advanced fibrosis.

16 The presence of more advanced NAFLD was associated with a significant reduction in the

17 g of therapeutic agents that counter against NAFLD progression.

18 veness of ketogenic diets toward alleviating NAFLD remains unclear.

19 ns in a 3-dimensional "risk space." Although NAFLD genomics sometimes appears to be "lost in translat

20 signaling networks that we define here as an NAFLD-Reactome.

21 OR, 0.96; P = .036) and a reduced risk of an NAFLD activity score of 4 or higher (ADH1B*2: OR, 0.83;

22 With multivariable analysis, NAFLD was an independent predictor of diabetes (adjusted

23 ], HCV [29% and 26%], ALD [16% and 25%], and NAFLD [8% and 9%]).

24 No drugs have yet been approved and NAFLD remains a major unmet need.

25 bserved between red meat and cholesterol and NAFLD with cirrhosis than without cirrhosis (P heterogen

26 Patients with HFpEF and NAFLD also appeared to have more advanced fibrosis inclu

27 The relationship between body mass index and NAFLD severity was significantly modified by ADH1B*2, ev

28 association between high body mass index and NAFLD severity.

29 are independently associated with NAFLD and NAFLD-related cirrhosis in a multiethnic population.

30 to ketogenic environment during obesity and NAFLD has the potential to aggravate hepatic mitochondri

31 ity in trial design, outcome prediction, and NAFLD surveillance.

32 ty liver disease (NAFLD) liver fat score and NAFLD fibrosis score.

33 le relationship between perceived stress and NAFLD.

34 nvironmental model of metabolic syndrome and NAFLD.

35 get in obesity and its complications T2D and NAFLD/NASH.

36 ms, hypoxia response, fatty acid uptake, and NAFLD.

37 cause of cancer-related death worldwide, and NAFLD has been identified as a rapidly emerging risk fac

38 latelet ratio index (APRI), FIB-4 as well as NAFLD fibrosis score (NFS).

39 sis and protected against obesity-associated NAFLD and insulin resistance in mice.

40 al and increased among patients who attended NAFLD education.

41 s that have been implicated as links between NAFLD and type 2 diabetes, cardiovascular disease, and n

42 advanced fibrosis was 0.65 and 0.66 for both NAFLD Fibrosis Score (NFS) and FIB-4.

43 hepatic comorbidities that are influenced by NAFLD are type 2 diabetes, cardiovascular disease, and i

44 ts and scoring systems exist to characterize NAFLD and NASH, liver biopsy is the only accepted method

45 ASDR for cirrhosis-NAFLD increased (APC = 0.29% [0.01%-0.59%]) but decrease

46 s enrol patients with histologically-defined NAFLD (non-alcoholic fatty liver disease) activity score

47 a cross-validation: a classifier to diagnose NAFLD (MRI PDFF >= 5%) and a fat fraction estimator to p

48 nd 13 patients with non-invasively diagnosed NAFLD-cirrhosis.

49 opulation at risk of NAFLD or with diagnosed NAFLD.

50 Diet-NAFLD associations were quantified by odds ratios and 95

51 ecrease in nonalcoholic fatty liver disease (NAFLD) Activity Score >=2 points without worsening of fi

52 Nonalcoholic fatty liver disease (NAFLD) affects a quarter of the adult population.

53 Non-alcoholic fatty liver disease (NAFLD) affects over 30% of adults in the United States.

54 common in non-alcoholic fatty liver disease (NAFLD) and appears to also be associated with myocardial

55 and rodent nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC).

56 genesis of nonalcoholic fatty liver disease (NAFLD) and insulin resistance.

57 feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss.

58 lopment of nonalcoholic fatty liver disease (NAFLD) and its progression to NASH are commonly accompan

59 valence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), have ste

60 resence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

61 jects with nonalcoholic fatty liver disease (NAFLD) and prediabetes (obese-NAFLD; n = 22).RESULTSInsu

62 he acronym nonalcoholic fatty liver disease (NAFLD) and provide suggestions on terminology that more

63 bolism and nonalcoholic fatty liver disease (NAFLD) are common in patients with human immunodeficienc

64 betes and non-alcoholic fatty liver disease (NAFLD) are increasing and may jointly become the major c

65 lopment of nonalcoholic fatty liver disease (NAFLD) are still poorly understood.

66 litus and non-alcoholic fatty liver disease (NAFLD) but studies examining the shape and content of th

67 ChREBP to nonalcoholic fatty liver disease (NAFLD) development in a mouse model for hepatic GSD 1a.

68 Nonalcoholic fatty liver disease (NAFLD) encompasses a range of conditions, from simple st

69 ), and the nonalcoholic fatty liver disease (NAFLD) fibrosis scores (NFS, n = 13,160).

70 actors for nonalcoholic fatty liver disease (NAFLD) from population-based studies, particularly in an

71 Worldwide, nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions and in parallel,

72 eatures of nonalcoholic fatty liver disease (NAFLD) in children that relate to improvement in liver h

73 ients with nonalcoholic fatty liver disease (NAFLD) in the absence of elevated enzymes is unclear.

74 on during non-alcoholic fatty liver disease (NAFLD) include remodeling of ketogenic flux and sustaine

75 Non-alcoholic fatty liver disease (NAFLD) is a complex chronic disease without any establis

76 Non-alcoholic fatty liver disease (NAFLD) is a frequent condition in obese patients and reg

77 Nonalcoholic fatty liver disease (NAFLD) is a global and growing health concern.

78 Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease world

79 Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with

80 Nonalcoholic fatty liver disease (NAFLD) is a leading etiology for chronic liver disease w

81 of which non-alcoholic fatty liver disease (NAFLD) is an increasingly recognised cause.

82 patients, nonalcoholic fatty liver disease (NAFLD) is associated with incident metabolic complicatio

83 Nonalcoholic fatty liver disease (NAFLD) is associated with obesity but also found in non-

84 Nonalcoholic fatty liver disease (NAFLD) is considered the next major health epidemic with

85 Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and causes serious health com

86 Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence in concert with the g

87 valence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide.

88 opment of non-alcoholic fatty liver disease (NAFLD) is largely unexplored.

89 Nonalcoholic fatty liver disease (NAFLD) is now the most common liver condition.

90 Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwid

91 Nonalcoholic fatty liver disease (NAFLD) is the most common pediatric chronic liver diseas

92 using the nonalcoholic fatty liver disease (NAFLD) liver fat score and NAFLD fibrosis score.

93 In non-alcoholic fatty liver disease (NAFLD) patients and obese mice, occupancy of SHP and DNM

94 siology of nonalcoholic fatty liver disease (NAFLD) remains unknown.

95 Nonalcoholic fatty liver disease (NAFLD) represents a burgeoning worldwide epidemic whose

96 e form of Non-alcoholic fatty liver disease (NAFLD), a chronic liver disease with a significant unmet

97 rus (HCV), nonalcoholic fatty liver disease (NAFLD), and alcohol-associated liver disease (ALD) are m

98 everity of nonalcoholic fatty liver disease (NAFLD), based on histologic analysis, compared with no a

99 creased in nonalcoholic fatty liver disease (NAFLD), but its relationship with liver inflammation is

100 ession of non-alcoholic fatty liver disease (NAFLD), but the underlying mechanisms are largely unknow

101 In nonalcoholic fatty liver disease (NAFLD), fibrosis is the most important factor contributi

102 diabetes, nonalcoholic fatty liver disease (NAFLD), or cardiovascular disease.

103 pathogenesis of non-alcoholic liver disease (NAFLD).

104 to assess nonalcoholic fatty liver disease (NAFLD).

105 ibrosis in nonalcoholic fatty liver disease (NAFLD).

106 s manifest nonalcoholic fatty liver disease (NAFLD).

107 anthin in non-alcoholic fatty liver disease (NAFLD).

108 opment of non-alcoholic fatty liver disease (NAFLD).

109 ents with non-alcoholic fatty liver disease (NAFLD).

110 ributor to nonalcoholic fatty liver disease (NAFLD).

111 iated with nonalcoholic fatty liver disease (NAFLD).

112 everity of nonalcoholic fatty liver disease (NAFLD).

113 opment of non-alcoholic fatty liver disease (NAFLD).

114 including nonalcoholic fatty liver disease (NAFLD).

115 agement of nonalcoholic fatty liver disease (NAFLD).

116 e liver as nonalcoholic fatty liver disease (NAFLD).

117 lopment of nonalcoholic fatty liver disease (NAFLD).

118 ontaneous non-alcoholic fatty liver disease (NAFLD).

119 including non-alcoholic fatty liver disease (NAFLD).

120 ion and metabolites are often altered during NAFLD progression.

121 olic dysfunction and oxidative stress during NAFLD.

122 ups (P < .01 for all NITs in F3 and for ELF, NAFLD Fibrosis Score, Fibrosis-4 (FIB-4), and liver stif

123 val [CI]: 90%, 99%) (98 of 102) accuracy for NAFLD diagnosis (sensitivity, 97% [95% CI: 90%, 100%], 6

124 adverse effects of pharmaceutical agents for NAFLD.

125 (HRs) and 95% confidence intervals (CIs) for NAFLD in association with all-cause and cause-specific m

126 algorithms that use radiofrequency data for NAFLD assessment, with MRI-derived proton density fat fr

127 re accurate in persons with risk factors for NAFLD at baseline, with AUROCs reaching 0.83.

128 1alpha) proteins as contributing factors for NAFLD.

129 he odds ratio (95% confidence intervals) for NAFLD comparing participants in the 5(th) quintile of PS

130 Investigations for NAFLD should be proposed in older patients with dyslipid

131 y complement other liver disease markers for NAFLD surveillance.

132 A care pathway for NAFLD within a large, integrated healthcare system provi

133 luded PWH undergoing a screening program for NAFLD using transient elastography.

134 consumption of fiber may reduce the risk for NAFLD and related advanced liver disease.

135 erstanding and develop a diagnostic tool for NAFLD using machine learning.

136 Over 70% of obese humans have NAFLD and ketogenic diets are common weight loss strateg

137 known NAFLD or who were suspected of having NAFLD were prospectively recruited between August 2015 a

138 4.3-36.3) NAFLD liver fat score, and a high NAFLD fibrosis score (HR, 12.2; 95% CI, 1.9-80.6) adjust

139 the U.S. population, PNPLA3 I148M and higher NAFLD liver fat and fibrosis scores were associated with

140 ifiers known to be relevant players in human NAFLD and which may determine key components of the heri

141 healthcare resources, strategies to improve NAFLD identification, staging, and promotion of lifestyl

142 In NAFLD, Escherichia coli LPS may increase liver damage by

143 ventional rodent studies (10,364 animals) in NAFLD to assess which variables influenced treatment res

144 ncrease the risk for systemic comorbidity in NAFLD.

145 diet supplemented with beta-cryptoxanthin in NAFLD.

146 iologically, which is likely dysregulated in NAFLD.

147 een explored to predict advanced fibrosis in NAFLD patients.

148 e involved in the progression of fibrosis in NAFLD.

149 s for the prediction of advanced fibrosis in NAFLD.

150 s might help to predict advanced fibrosis in NAFLD.

151 BA levels were significantly higher in NAFLD with advanced compared with earlier stages of live

152 consistently associated with improvement in NAFLD.

153 study we define two distinct types of NI in NAFLD: inclusions bounded by the nuclear membrane, conta

154 stiffness on MRE and fibrosis progression in NAFLD.

155 was associated with a 33% risk reduction in NAFLD.

156 t of cardiac dysfunction on fibrosis risk in NAFLD.

157 ture on the impact of cellular senescence in NAFLD/NASH and discuss the effectiveness and safety of n

158 bariatric surgery guidelines should include NAFLD as a comorbid indication when determining eligibil

159 and aggravating high-fat diet (HFD)-induced NAFLD.

160 es the effect of HuR knockout in HFD-induced NAFLD.

161 There is limited data investigating NAFLD in HIV mono-infection and histologically defined d

162 Ninety-two Iranian NAFLD outpatients were recruited for this 12-week, singl

163 Here, we summarize key NAFLD risk genes and illustrate their interactions in a

164 Materials and Methods Adults with known NAFLD or who were suspected of having NAFLD were prospec

165 tities, detailed long-term outcomes of large NAFLD-associated HCC cohorts are lacking.

166 ASDR for LC-NAFLD and ALD increased annually by 1.42% (1.00%-1.83%)

167 Lean NAFLD was defined when a body mass index was <25 kg/m2.

168 We aimed to investigate lean NAFLD in patients living with HIV.

169 The prevalence of lean NAFLD patients in the whole cohort was 13.9%.

170 The proportions of lean NAFLD patients who were metabolically abnormal or had el

171 e gut microbiome in the pathogenesis of lean NAFLD.

172 Patients with lean NAFLD had a more favorable metabolic and histological pr

173 Patients with lean NAFLD had higher serum secondary BA and FGF19 levels and

174 ta show that enhanced ChREBP activity limits NAFLD development in GSD 1a by balancing hepatic TG prod

175 f GIE and Curcuminoids, resulting in a lower NAFLD activity score.

176 tive species are administered in three mouse NAFLD models to evaluate their effects on liver damage.

177 1 Asians with biopsy-proven NAFLD and 31 non-NAFLD controls are analyzed using 16S rRNA sequencing; a

178 ion models outperformed existing noninvasive NAFLD prediction tools.

179 cal profile compared with those with nonlean NAFLD (P < 0.05 for all).

180 , 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively.

181 fter glucose ingestion in obese-NL and obese-NAFLD is due to an increase in insulin secretion, withou

182 liver disease (NAFLD) and prediabetes (obese-NAFLD; n = 22).RESULTSInsulin sensitivity progressively

183 Six subjects in the obese-NAFLD group were also evaluated before and after a diet-

184 rom the lean-NL to the obese-NL to the obese-NAFLD groups.

185 rom the lean-NL to the obese-NL to the obese-NAFLD groups.

186 54% of NAFLD patients had a NAFLD fibrosis score consistent wit

187 lt individuals with ultrasound assessment of NAFLD from the Third National Health and Nutrition Exami

188 Identification of this cohort of NAFLD patients is paramount, given the associated poorer

189 lying genetic and epigenetic contributors of NAFLD have not been fully explored.

190 We determined the natural course of NAFLD (liver fat [LFAT]) and type 2 diabetes mellitus (T

191 BMP signaling is an important determinant of NAFLD in a murine model and is associated with NAFLD in

192 55 system plays a role in the development of NAFLD and NASH by activating ACC.

193 The development of NAFLD was associated with overexpression of the critical

194 ffspring body composition and development of NAFLD while focusing on proteomic-based analysis of the

195 ex-specific variations in the development of NAFLD.

196 that confer high risk for the development of NAFLD: hyperglycemia, insulin resistance, and dyslipidem

197 Early diagnosis of NAFLD is important, as this can help prevent irreversibl

198 Distinguishing features of NAFLD-associated HCC patients in the cirrhosis and non-c

199 Moreover, MCJ levels in the liver of NAFLD patients are elevated relative to healthy subjects

200 viduals, we associated histologic markers of NAFLD severity with significant decreases in viral diver

201 erformed in the diet-induced animal model of NAFLD (DIAMOND).

202 igh-cholesterol diet-induced rodent model of NAFLD, we observed a progressive stepwise reduction in t

203 ove NASH in the diet-induced animal model of NAFLD.

204 In rodent models of NAFLD, treatment with a surrogate of TVB-2640, a pharmac

205 tes per week) demonstrated 40% lower odds of NAFLD, whereas transportation-related PA was associated

206 In the race-specific analysis, the PAFs of NAFLD for all-cause mortality (9.3%; 95% CI, 4.0, 14.6)

207 Here we review the pathogenesis of NAFLD and the impact of AMPK activity state on hepatic s

208 selected variants in the pathophysiology of NAFLD and highlight opportunities for future clinical re

209 NI in 77 paraffin-embedded patients of NAFLD including NAFL and non-alcoholic steatohepatitis (

210 steatohepatitis (NASH), an advanced phase of NAFLD.

211 n-invasive surrogate marker and predictor of NAFLD.

212 tween perceived stress and the prevalence of NAFLD in a large sample of apparently healthy men and wo

213 The prevalence of NAFLD was 27.8%.

214 y associated with an increased prevalence of NAFLD, supporting a possible relationship between percei

215 ith a 2.1-fold increase in the prevalence of NAFLD.

216 tems in persons with a higher probability of NAFLD at baseline.

217 stronger association with risk reduction of NAFLD in women, women showed a lower tendency of meeting

218 g time increased significantly regardless of NAFLD status.

219 ribed adaptations underlying the reversal of NAFLD by KD: That is, markedly altered hepatic mitochond

220 rajectory of a child, increasing the risk of NAFLD and other cardiometabolic diseases.

221 utcomes in the general population at risk of NAFLD or with diagnosed NAFLD.

222 periods and in persons with a higher risk of NAFLD, with AUROC values reaching 0.83.

223 APRI allows screening of NAFLD as well as fibrosis in obese patients.

224 ol consumption (g/d) reduced the severity of NAFLD in patients with ADH1B*1 or ADH1B*2.

225 moderate alcohol consumption and severity of NAFLD.

226 cohol consumption and histologic severity of NAFLD.

227 bgroups according to histological spectra of NAFLD or fibrosis severity.

228 atients without this inflammatory subtype of NAFLD, with annual all-cause mortality rate of 25.56 per

229 artrate Delayed-Release for the Treatment of NAFLD in Children) clinical trial.

230 ial for use as a target for the treatment of NAFLD.

231 Guidelines for Americans (PA Guidelines) on NAFLD are lacking.

232 argets across multiple pathways that promote NAFLD development and influence several progressive outc

233 me profiles of 171 Asians with biopsy-proven NAFLD and 31 non-NAFLD controls are analyzed using 16S r

234 ultiethnic adult patients with biopsy-proven NAFLD enrolled into 4 different studies conducted by the

235 as performed in a cohort of 83 biopsy-proven NAFLD patients and 13 patients with non-invasively diagn

236 02 patients (62.7% women) with biopsy-proven NAFLD who underwent contemporaneous MRE and liver biopsy

237 chia coli LPS in patients with biopsy-proven NAFLD, 25 simple steatosis (nonalcoholic fatty liver) an

238 nisms to warrant stress management to reduce NAFLD.

239 signaling in the development of age-related NAFLD.

240 KD rapidly reverses NAFLD and insulin resistance despite increasing circulat

241 In the United States, NAFLD and its subtype, nonalcoholic steatohepatitis, aff

242 lic fatty liver disease and steatohepatitis (NAFLD/NASH) and insulin resistance.

243 o identify additional biomarkers to stratify NAFLD patients without cirrhosis who are at risk for HCC

244 Despite evidence that NAFLD-associated HCC may arise in the absence of cirrhos

245 The NAFLD Care Pathway includes: (1) patient education (2) v

246 The NAFLD-HCC patients had a trend for higher recurrence-fre

247 The NAFLD-Reactome model expands these pathways and allows f

248 re compared with transient elastography, the NAFLD fibrosis score (NFS) and FIB-4 index.

249 vival rates were significantly higher in the NAFLD-HCC cases compared to HBV-HCC (HR = 0.35, 95% CI 0

250 Within the NAFLD group, 18% did not have cirrhosis or advanced fibr

251 iated with the onset and progression of this NAFLD phenotype.

252 hydroxysteroid 17-beta dehydrogenase 13) to NAFLD and expand the associated underlying mechanisms us

253 is the most important factor contributing to NAFLD-associated morbidity and mortality.

254 We examined dietary factors in relation to NAFLD risk in African Americans, Japanese Americans, Lat

255 emerges as an alternative approach to treat NAFLD.

256 y be a novel therapeutic avenue for treating NAFLD.

257 After treatments, NAFLD-related HCC patients had longer overall but not re

258 erative liver biopsies were classified using NAFLD activity score (NAS) and steatosis, activity and f

259 the risk of NASH and fibrosis in adults with NAFLD regardless of alcohol consumption status.

260 ndex (BMI) was independently associated with NAFLD (aOR 1.2 95% CI 1.08-1.34), and type 2 diabetes wa

261 ry factors are independently associated with NAFLD and NAFLD-related cirrhosis in a multiethnic popul

262 FLD in a murine model and is associated with NAFLD in humans.

263 PAF for all-cause mortality associated with NAFLD was 7.5% (95% CI, 3.0, 12.0).

264 ndividuals have risk factors associated with NAFLD, but the majority do not develop advanced liver di

265 005) intakes were positively associated with NAFLD, while dietary fiber intake (P trend = 0.003) was

266 diabetes-specific deaths are associated with NAFLD.

267 In children with NAFLD, dynamic changes in serum ALT and GGT are associat

268 e PA Guidelines was lower in the cohort with NAFLD, with sex- and ethnicity-based differences.

269 ng protein HuR (ELAVL1) forms complexes with NAFLD-relevant transcripts.

270 taging and clinical features correlated with NAFLD among patients with heart failure with preserved e

271 pe of PA remained stable in individuals with NAFLD except for a downtrend in transportation-related P

272 PA Guidelines was lower in individuals with NAFLD versus those without NAFLD.

273 contributes to steatosis in individuals with NAFLD.

274 in stimulate hepatic DNL in individuals with NAFLD.

275 reased mortality risk among individuals with NAFLD; therefore, the population attributable fractions

276 dy was performed for adult participants with NAFLD and control participants without liver disease.

277 lassifier to differentiate participants with NAFLD versus participants without NAFLD and a fat fracti

278 a study of fecal viromes from patients with NAFLD and control individuals, we associated histologic

279 or, TVB-2640 in particular, in patients with NAFLD and nonalcoholic steatohepatitis.

280 review addressing HCC risk in patients with NAFLD and provide Best Practice Advice statements to add

281 R55 expression in the liver of patients with NAFLD compared with individuals without obesity and with

282 tile range, 26.5-50.7 months), patients with NAFLD had higher incidences of diabetes (4.74 [95% confi

283 ble-blind phase 2 trial of 104 patients with NAFLD in the United Kingdom.

284 addressing HCC surveillance in patients with NAFLD outside the context of established cirrhosis.

285 inicians with respect to which patients with NAFLD should undergo HCC surveillance, optimal screening

286 velopment of cirrhosis between patients with NAFLD who underwent bariatric surgery and a well-matched

287 In a randomized trial of patients with NAFLD, 1 year of administration of a synbiotic combinati

288 ion of the fecal microbiome in patients with NAFLD.

289 es, and diagnostic approach to patients with NAFLD.

290 observed in insulin-resistant patients with NAFLD.

291 trategy for otherwise eligible patients with NAFLD.

292 cellular carcinoma (HCC) among patients with NAFLD.

293 e risk of cirrhosis and HCC in patients with NAFLD.

294 ) was similar between cases with and without NAFLD (3% vs 2%).

295 Of the 53 cases without NAFLD, 15 (28%) had advanced fibrosis.

296 leisure time was noted in the cohort without NAFLD.

297 pants with NAFLD versus participants without NAFLD and a fat fraction estimator.

298 n among those who were lean patients without NAFLD (61.9% vs 48.9% and 36.7% vs 24.2%, respectively).

299 individuals with NAFLD versus those without NAFLD.

300 95] per 100 person-years) than those without NAFLD.